Jason A Bartos1, Demetris Yannopoulos. 1. Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: The ultimate goal of cardiopulmonary resuscitation is long-term neurologically intact survival. Despite numerous well-designed studies, the medications currently used in advanced cardiac life support have not demonstrated success in this regard. This review describes the novel therapeutics under investigation to improve functional recovery and survival. RECENT FINDINGS: Whereas current medications focus on achieving return of spontaneous circulation and improved hemodynamics, novel therapies currently in development are focused on improving cellular survival and function by preventing metabolic derangement, protecting mitochondria, and preventing cell death caused by cardiac arrest. Improved cardiac and neurologic function and survival benefits have been observed using animal models of cardiopulmonary arrest. SUMMARY: Although substantial data have shown benefits using robust animal models, further human studies are necessary to investigate the potential long-term benefits of these therapies.
PURPOSE OF REVIEW: The ultimate goal of cardiopulmonary resuscitation is long-term neurologically intact survival. Despite numerous well-designed studies, the medications currently used in advanced cardiac life support have not demonstrated success in this regard. This review describes the novel therapeutics under investigation to improve functional recovery and survival. RECENT FINDINGS: Whereas current medications focus on achieving return of spontaneous circulation and improved hemodynamics, novel therapies currently in development are focused on improving cellular survival and function by preventing metabolic derangement, protecting mitochondria, and preventing cell death caused by cardiac arrest. Improved cardiac and neurologic function and survival benefits have been observed using animal models of cardiopulmonary arrest. SUMMARY: Although substantial data have shown benefits using robust animal models, further human studies are necessary to investigate the potential long-term benefits of these therapies.
Authors: Jason C Schultz; Nicolas Segal; Emily Caldwell; James Kolbeck; Scott McKnite; Nick Lebedoff; Menekhem Zviman; Tom P Aufderheide; Demetris Yannopoulos Journal: Crit Care Med Date: 2011-12 Impact factor: 7.598
Authors: Demetris Yannopoulos; Nicolas Segal; Scott McKnite; Tom P Aufderheide; Keith G Lurie Journal: Crit Care Med Date: 2012-05 Impact factor: 7.598
Authors: Jason Schultz; Nicolas Segal; James Kolbeck; Scott McKnite; Emily Caldwell; Demetris Yannopoulos Journal: Resuscitation Date: 2011-08-22 Impact factor: 5.262
Authors: Cameron Dezfulian; Aleksey Alekseyenko; Kunjan R Dave; Ami P Raval; Rose Do; Francis Kim; Miguel A Perez-Pinzon Journal: Nitric Oxide Date: 2012-03-30 Impact factor: 4.427
Authors: Lawrence Sherman; James Niemann; Scott T Youngquist; Atman P Shah; John P Rosborough Journal: Resuscitation Date: 2011-10-10 Impact factor: 5.262
Authors: Richdeep S Gill; Tze-Fun Lee; Consolato Sergi; David L Bigam; Po-Yin Cheung Journal: Intensive Care Med Date: 2012-05-10 Impact factor: 17.440
Authors: Demetris Yannopoulos; Jason A Bartos; Stephen A George; George Sideris; Sebastian Voicu; Brett Oestreich; Timothy Matsuura; Kadambari Shekar; Jennifer Rees; Tom P Aufderheide Journal: Resuscitation Date: 2016-10-19 Impact factor: 5.262